Sudhir Agrawal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9228435/publications.pdf

Version: 2024-02-01

181 papers	9,216 citations	28190 55 h-index	53109 85 g-index
184 all docs	184 docs citations	184 times ranked	6252 citing authors

#	Article	IF	Citations
1	Antisense oligonucleotides: towards clinical trials. Trends in Biotechnology, 1996, 14, 376-387.	4.9	262
2	Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey. Antisense Research and Development, 1994, 4, 201-206.	3.3	239
3	Efficient methods for attaching non-radioactive labels to the 5â€² ends of synthetic oligodeoxyribonucleotides. Nucleic Acids Research, 1986, 14, 6227-6245.	6.5	225
4	MDM2 Is a Negative Regulator of p21 , Independent of p53. Journal of Biological Chemistry, 2004, 279, 16000-16006.	1.6	223
5	Antisense therapeutics. Current Opinion in Chemical Biology, 1998, 2, 519-528.	2.8	212
6	Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscular Disorders, 1999, 9, 330-338.	0.3	190
7	In vivo studies with antisense oligonucleotides. Trends in Pharmacological Sciences, 1997, 18, 12-18.	4.0	180
8	Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11636-11641.	3.3	179
9	Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochemical Pharmacology, 1996, 51, 173-182.	2.0	167
10	Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene, 2004, 23, 8105-8117.	2.6	165
11	Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1489, 53-67.	2.4	160
12	Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis. Clinical Cancer Research, 2006, 12, 5231-5241.	3.2	136
13	Antisense oligonucleotides as antiviral agents. Trends in Biotechnology, 1992, 10, 152-158.	4.9	135
14	Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochemical Pharmacology, 1995, 50, 571-576.	2.0	133
15	Antisense therapeutics: is it as simple as complementary base recognition?. Trends in Molecular Medicine, 2000, 6, 72-81.	2.6	125
16	Pharmacokinetics of an antiâ€"human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*. Clinical Pharmacology and Therapeutics, 1995, 58, 44-53.	2.3	122
17	Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM) Tj ETQq1 1 0.784314 rgBT /Ove Pharmacology, 1995, 49, 929-939.	2.0	121
18	Antisense and siRNA as agonists of Toll-like receptors. Nature Biotechnology, 2004, 22, 1533-1537.	9.4	119

#	Article	IF	Citations
19	Dual Blockade of Cyclic AMP Response Element- (CRE) and AP-1-directed Transcription by CRE-transcription Factor Decoy Oligonucleotide. Journal of Biological Chemistry, 1999, 274, 1573-1580.	1.6	113
20	Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway. Oncogene, 2005, 24, 7238-7247.	2.6	111
21	Oligodeoxynucleoside methylphosphonates: synthesis and enzymic degradation. Tetrahedron Letters, 1987, 28, 3539-3542.	0.7	109
22	Self-stabilized antisense oligodeoxynucleotide phosphorothioates: properties and anti-HIV activity. Nucleic Acids Research, 1993, 21, 2729-2735.	6.5	103
23	Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. Journal of Neurochemistry, 2008, 79, 426-436.	2.1	100
24	In vivo stability, disposition and metabolism of a â€œhybridâ€•oligonucleotide phosphorothioate in rats. Biochemical Pharmacology, 1995, 50, 545-556.	2.0	97
25	Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6925-6930.	3.3	95
26	Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice. Oligonucleotides, 1997, 7, 495-502.	4.4	93
27	Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. International Journal of Cancer, 2001, 93, 172-178.	2.3	87
28	Thermal stressâ€“induced HSP70 mediates protection against intrapancreatic trypsinogen activation and acute pancreatitis in rats. Gastroenterology, 2002, 122, 156-165.	0.6	87
29	Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate, 2003, 54, 194-205.	1.2	86
30	Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors. Clinical Cancer Research, 2006, 12, 577-583.	3.2	86
31	Conjugation of Ligands at the 5â€˜-End of CpG DNA Affects Immunostimulatory Activity. Bioconjugate Chemistry, 2002, 13, 966-974.	1.8	84
32	Antisense and/or Immunostimulatory Oligonucleotide Therapeutics. Current Cancer Drug Targets, 2001, 1, 197-209.	0.8	83
33	Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression. Molecular Medicine, 1999, 5, 21-34.	1.9	78
34	Accessible 5â€²-end of CpG-containing Phosphorothioate Oligodeoxynucleotides is essential for immunostimulatory activity. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2585-2588.	1.0	78
35	Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties. Bioorganic and Medicinal Chemistry, 2000, 8, 275-284.	1.4	77
36	Medicinal chemistry and therapeutic potential of CpG DNA. Trends in Molecular Medicine, 2002, 8, 114-121.	3.5	76

#	Article	IF	Citations
37	Heat shock protein 70 prevents secretagogue-induced cell injury in the pancreas by preventing intracellular trypsinogen activation. Journal of Clinical Investigation, 2000, 106, 81-89.	3.9	76
38	Mixed Backbone Oligonucleotides: Improvement in Oligonucleotide-induced Toxicity In Vivo. Oligonucleotides, 1998, 8, 135-139.	4.4	75
39	Pharmacokinetics, Biodistribution, and Stability of Capped Oligodeoxynucleotide Phosphorothioates in Mice. Antisense Research and Development, 1993, 3, 277-284.	3.3	73
40	Cooperative Inhibition of Renal Cancer Growth by Anti-Epidermal Growth Factor Receptor Antibody and Protein Kinase A Antisense Oligonucleotide. Journal of the National Cancer Institute, 1998, 90, 1087-1998.	3.0	72
41	Effect of chemical modifications of cytosine and guanine in a cpg-motif of oligonucleotides: structureâ€“immunostimulatory activity relationships. Bioorganic and Medicinal Chemistry, 2001, 9, 807-813.	1.4	71
42	'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Research, 2002, 30, 4460-4469.	6.5	70
43	Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 13750-13755.	3.3	69
44	A novelMDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. International Journal of Cancer, 2000, 88, 804-809.	2.3	68
45	A Toll-Like Receptor 7, 8, and 9 Antagonist Inhibits Th1 and Th17 Responses and Inflammasome Activation in a Model of IL-23-Induced Psoriasis. Journal of Investigative Dermatology, 2013, 133, 1777-1784.	0.3	66
46	TLR9 Agonist Protects Mice from Radiation-Induced Gastrointestinal Syndrome. PLoS ONE, 2012, 7, e29357.	1.1	65
47	TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12468-12473.	3.3	63
48	Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Research, 2003, 31, 2393-2400.	6.5	62
49	Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Research, 2013, 41, 3947-3961.	6.5	62
50	Large-Scale Synthesis, Purification, and Analysis of Oligodeoxynucleotide Phosphorothioates. Antisense Research and Development, 1994, 4, 185-199.	3.3	61
51	Perspectives in antisense therapeutics. , 1997, 76, 151-160.		61
52	Stabilization of the MDM2 Oncoprotein by Mutant p53. Journal of Biological Chemistry, 2001, 276, 6874-6878.	1.6	60
53	Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models. Clinical Cancer Research, 2004, 10, 1263-1273.	3.2	60
54	Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2â€²-o- methyloligoribonucleotides. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2929-2934.	1.0	59

#	Article	IF	Citations
55	A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14303-14308.	3.3	58
56	Oral administration of a synthetic agonist of Toll-like receptor 9 potently modulates peanut-induced allergy in mice. Journal of Allergy and Clinical Immunology, 2007, 120, 631-637.	1.5	58
57	Site of chemical modifications in CpG containing phosphorothiate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3453-3458.	1.0	56
58	Application of XIAP Antisense to Cancer and Other Proliferative Disorders: Development of AEG35156/GEM(R)640. Annals of the New York Academy of Sciences, 2005, 1058, 215-234.	1.8	56
59	Chemotherapy and chemosensitization of nonâ€“small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Molecular Cancer Therapeutics, 2006, 5, 1585-1592.	1.9	56
60	Modifications Incorporated in CpG Motifs of Oligodeoxynucleotides Lead to Antagonist Activity of Toll-like Receptors 7 and 9. Journal of Medicinal Chemistry, 2009, 52, 5108-5114.	2.9	56
61	Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 217-235.	1.8	54
62	A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice. Autoimmunity, 2013, 46, 419-428.	1.2	54
63	Role of toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle. Human Molecular Genetics, 2014, 23, 2604-2617.	1.4	54
64	Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and Mechanisms. Current Cancer Drug Targets, 2005, 5, 43-49.	0.8	53
65	Solid-phase stereoselective synthesis of oligonucleoside phosphorothioates: The nucleoside bicyclic oxazaphospholidines as novel synthons. Tetrahedron Letters, 1998, 39, 2491-2494.	0.7	52
66	RAGE Enhances TLR Responses through Binding and Internalization of RNA. Journal of Immunology, 2016, 197, 4118-4126.	0.4	51
67	An In Situ Autologous Tumor Vaccination with Combined Radiation Therapy and TLR9 Agonist Therapy. PLoS ONE, 2012, 7, e38111.	1.1	51
68	Ion-exchange high-performance liquid chromatography analysis of oligodeoxyribonucleotide phosphorothioates. Analytical Biochemistry, 1992, 200, 342-346.	1.1	49
69	Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1051-1054.	1.0	48
70	Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms. Molecular Medicine, 2002, 8, 185-199.	1.9	48
71	Combined Targeting of Epidermal Growth Factor Receptor and MDM2 by Gefitinib and Antisense MDM2 Cooperatively Inhibit Hormone-Independent Prostate Cancer. Clinical Cancer Research, 2004, 10, 4858-4864.	3.2	48
72	In VivoMetabolic Profile of a Phosphorothioate Oligodeoxyribonucleotide. Oligonucleotides, 1997, 7, 159-165.	4.4	47

#	Article	IF	Citations
73	Potent CpG oligonucleotides containing phosphodiester linkages: in vitro and in vivo immunostimulatory properties. Biochemical and Biophysical Research Communications, 2002, 297, 83-90.	1.0	47
74	Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers. Clinical Cancer Research, 2011, 17, 6531-6541.	3.2	47
75	Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorganic and Medicinal Chemistry, 2001, 9, 2803-2808.	1.4	45
76	Modulation of immunostimulatory activity of CpG oligonucleotides by site-Specific deletion of nucleobases. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2263-2267.	1.0	44
77	Treatment of Mammary Carcinomas in HER-2 Transgenic Mice through Combination of Genetic Vaccine and an Agonist of Toll-Like Receptor 9. Clinical Cancer Research, 2009, 15, 1575-1584.	3.2	44
78	Effects of synthetic oligonucleotides on human complement and coagulationâˆ—. Biochemical Pharmacology, 1997, 53, 1123-1132.	2.0	43
79	The Multiple Inhibitory Mechanisms of GEM 91Â®, agagAntisense Phosphorothioate Oligonucleotide, for Human Immunodeficiency Virus Type 1. AIDS Research and Human Retroviruses, 1997, 13, 545-554.	0.5	42
80	Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA. Annals of the New York Academy of Sciences, 2003, 1002, 30-42.	1.8	42
81	Oligodeoxyribonucleotide-Based Antagonists for Toll-Like Receptors 7 and 9. Journal of Medicinal Chemistry, 2009, 52, 551-558.	2.9	41
82	Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. International Journal of Oncology, 2018, 53, 1193-1203.	1.4	41
83	Toxicologic Effects of an Oligodeoxynucleotide Phosphorothioate and Its Analogs Following Intravenous Administration in Rats. Oligonucleotides, 1997, 7, 575-584.	4.4	39
84	Mixed-Backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3269-3274.	1.0	39
85	EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells. , 1999, 80, 589-594.		39
86	Secondary structures in CpG oligonucleotides affect immunostimulatory activity. Biochemical and Biophysical Research Communications, 2003, 306, 948-953.	1.0	39
87	Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA. Bioorganic and Medicinal Chemistry, 2003, 11, 459-464.	1.4	38
88	Peptide Conjugation at the 5â€²-End of Oligodeoxynucleotides Abrogates Toll-Like Receptor 9-Mediated Immune Stimulatory Activity. Bioconjugate Chemistry, 2010, 21, 39-45.	1.8	38
89	Cellular Distribution of Phosphorothioate Oligonucleotide Following Intravenous Administration in Mice. Oligonucleotides, 1998, 8, 451-458.	4.4	37
90	Design, Synthesis, and Immunostimulatory Properties of CpG DNAs Containing Alkyl-Linker Substitutions:Â Role of Nucleosides in the Flanking Sequences. Journal of Medicinal Chemistry, 2002, 45, 4540-4548.	2.9	37

#	Article	IF	Citations
91	Cutting Edge: The UNC93B1 Tyrosine-Based Motif Regulates Trafficking and TLR Responses via Separate Mechanisms. Journal of Immunology, 2014, 193, 3257-3261.	0.4	37
92	Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis. Atherosclerosis, 2017, 261, 26-36.	0.4	37
93	Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy. Molecular Cancer Therapeutics, 2006, 5, 2106-2114.	1.9	36
94	A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action. Clinical Cancer Research, 2009, 15, 6921-6930.	3.2	35
95	Antitumor Activity and Immune Response Induction of a Dual Agonist of Toll-Like Receptors 7 and 8. Molecular Cancer Therapeutics, 2010, 9, 1788-1797.	1.9	35
96	Hoogsteen DNA Duplexes of 3â€˜â˜’3â€˜- and 5â€˜â˜’5â€˜-Linked Oligonucleotides and Triplex Formation with RNA and DNA Pyrimidine Single Strands:Â Experimental and Molecular Modeling Studies. Biochemistry, 1996, 35, 15332-15339.	1.2	34
97	Pharmacokinetics and Metabolism of an Oligodeoxynucleotide Phosphorothioate (GEM91Â®) in Cynomolgus Monkeys Following Intravenous Infusion. Oligonucleotides, 1998, 8, 43-52.	4.4	33
98	Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. International Immunopharmacology, 2004, 4, 127-138.	1.7	33
99	Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages. Nucleic Acids Research, 2002, 30, 1613-1619.	6.5	32
100	Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. International Journal of Radiation Oncology Biology Physics, 2004, 58, 336-343.	0.4	32
101	Tilsotolimod with Ipilimumab Drives Tumor Responses in Antiâ€“PD-1 Refractory Melanoma. Cancer Discovery, 2021, 11, 1996-2013.	7.7	32
102	Growth arrest and induction of apoptosis in breast cancer cells by antisense depletion of protein kinase A-RI alpha subunit: p53-independent mechanism of action. Molecular and Cellular Biochemistry, 1999, 195, 25-36.	1.4	31
103	Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8. Biochemical and Biophysical Research Communications, 2009, 386, 443-448.	1.0	31
104	CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents. Biochemical and Biophysical Research Communications, 2003, 300, 853-861.	1.0	30
105	Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine, 2005, 23, 2614-2622.	1.7	30
106	Enzymatic Synthesis of Stereoregular (All Rp) Oligonucleotide Phosphorothioate and Its Properties. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 985-990.	0.4	29
107	Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells. Biochemical and Biophysical Research Communications, 2003, 310, 1133-1139.	1.0	29
108	In VivoPharmacokinetics of Phosphorothioate Oligonucleotides Containing Contiguous Guanosines. Oligonucleotides, 1997, 7, 245-249.	4.4	28

#	Article	IF	Citations
109	Antisense depletion of RIÎ± subunit of protein kinase A induces apoptosis and growth arrest in human breast cancer cells. Breast Cancer Research and Treatment, 1998, 49, 97-107.	1.1	28
110	Impact of mixed-backbone oligonucleotides on target binding affinity and target cleaving specificity and selectivity by Escherichia coli RNase H. Bioorganic and Medicinal Chemistry, 1998, 6, 1695-1705.	1.4	28
111	Antisense-MDM2 Sensitizes LNCaP Prostate Cancer Cells to Androgen Deprivation, Radiation, and the Combination In Vivo. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1151-1160.	0.4	28
112	Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Research, 2000, 48, 187-196.	1.9	27
113	Effect of Aspirin on Protein Binding and Tissue Disposition of Oligonucleotide Phosphorothioate in Rats. Journal of Drug Targeting, 1998, 5, 303-312.	2.1	26
114	The Roles of E6-AP and MDM2 in p53 Regulation in Human Papillomavirus-Positive Cervical Cancer Cells. Oligonucleotides, 2000, 10, 17-27.	4.4	26
115	Impact of Secondary Structure of Toll-Like Receptor 9 Agonists on Interferon Alpha Induction. Antimicrobial Agents and Chemotherapy, 2008, 52, 4320-4325.	1.4	26
116	Toll-like Receptor 7 Selective Synthetic Oligoribonucleotide Agonists: Synthesis and Structureâ^'Activity Relationship Studies. Journal of Medicinal Chemistry, 2009, 52, 6871-6879.	2.9	26
117	Was Induction of HIV-1 Through TLR9?. Journal of Immunology, 2003, 171, 1621-1622.	0.4	25
118	â€˜Cycliconsâ€™ as hybridization-based fluorescent primer-probes: synthesis, properties and application in real-time PCR. Bioorganic and Medicinal Chemistry, 2000, 8, 1911-1916.	1.4	24
119	Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochemical Pharmacology, 1996, 52, 1537-1544.	2.0	23
120	Agonists of Toll-like Receptor 9 Containing Synthetic Dinucleotide Motifs. Journal of Medicinal Chemistry, 2007, 50, 6411-6418.	2.9	23
121	Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate, 2008, 68, 599-609.	1.2	23
122	Design, biochemical, biophysical and biological properties of cooperative antisense oligonucleotides. Nucleic Acids Research, 1995, 23, 3578-3584.	6.5	22
123	Novel MDM2 p53-Independent Functions Identified through RNA Silencing Technologies. Annals of the New York Academy of Sciences, 2005, 1058, 205-214.	1.8	22
124	Coadministration of Telomerase Genetic Vaccine and a Novel TLR9 Agonist in Nonhuman Primates. Molecular Therapy, 2009, 17, 1804-1813.	3.7	22
125	Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate, 2004, 60, 187-196.	1.2	20
126	Solid-phase stereoselective synthesis of 2â€²-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2539-2544.	1.0	19

#	Article	IF	Citations
127	Biodistribution and Metabolism of a Mixed Backbone Oligonucleotide (GEM 231) Following Single and Multiple Dose Administration in Mice. Oligonucleotides, 2000, 10, 333-345.	4.4	19
128	Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice. International Immunopharmacology, 2005, 5, 981-991.	1.7	19
129	PKA knockdown enhances cell killing in response to radiation and androgen deprivation. International Journal of Cancer, 2011, 128, 962-973.	2.3	19
130	Bioreversible oligonucleotide conjugates by site-specific derivatization. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 871-876.	1.0	18
131	Cell binding, uptake and cytosolic partition of HIV anti-gag Phosphodiester oligonucleotides 3â€²-linked to cholesterol derivatives in macrophages. Bioorganic and Medicinal Chemistry, 1999, 7, 2263-2269.	1.4	18
132	A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine. Vaccine, 2010, 28, 3522-3530.	1.7	18
133	Novel Oligonucleotides Containing Two 3â€²-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity. Journal of Medicinal Chemistry, 2011, 54, 3027-3036.	2.9	18
134	Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494. Molecular Therapy - Nucleic Acids, 2017, 7, 61-70.	2.3	18
135	N-pent-4-enoyl (PNT) group as a universal nucleobase protector: Applications in the rapid and facile synthesis of oligonucleotides, analogs, and conjugates. Tetrahedron, 1997, 53, 2731-2750.	1.0	16
136	Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. International Immunopharmacology, 2004, 4, 851-862.	1.7	16
137	Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications. Nucleic Acids Research, 2006, 34, 3231-3238.	6.5	16
138	Synthetic oligoribonucleotides containing arabinonucleotides act as agonists of TLR7 and 8. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2044-2047.	1.0	16
139	Synthesis of di-, tri-, and tetrameric building blocks with novel carbamate internucleoside linkages and their incorporation into oligonucleotides. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1065-1070.	1.0	14
140	3â€²-3â€²-linked oligonucleotides: Synthesis and stability studies. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 827-832.	1.0	14
141	Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 2103-2108.	1.0	14
142	A Mild and Efficient Solid-Support Synthesis of Novel Oligonucleotide Conjugates. Bioconjugate Chemistry, 1998, 9, 283-291.	1.8	14
143	Synthesis and immunological activities of novel agonists of toll-like receptor 9. Cellular Immunology, 2010, 263, 105-113.	1.4	14
144	Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists. Cellular Immunology, 2011, 270, 126-134.	1.4	14

#	Article	IF	Citations
145	Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors. Immuno-Oncology Technology, 2019, 3, 15-23.	0.2	14
146	The use of gaseous ammonia for the deprotection and cleavage steps during the solid-phase synthesis of oligonucleotides, and analogs. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1443-1448.	1.0	13
147	The Evolution of Antisense Oligonucleotide Chemistryâ€"A Personal Journey. Biomedicines, 2021, 9, 503.	1.4	13
148	Synthesis, biophysical properties, and stability studies of mixed backbone oligonucleotides containing segments of methylphosphotriester internucleotidic linkages. Tetrahedron, 1996, 52, 14419-14436.	1.0	12
149	Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. International Journal of Oncology, 2004, 24, 901.	1.4	12
150	Antisense MDM2 Enhances E2F1-Induced Apoptosis and the Combination Sensitizes Androgen-Dependent and Androgen-Independent Prostate Cancer Cells to Radiation. Molecular Cancer Research, 2008, 6, 1742-1754.	1.5	12
151	Mixed backbone oligonucleotides containing internucleotidic primary phosphoramidate linkages. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2663-2668.	1.0	11
152	Restoration of ÃŸ-Globin Gene Expression in Mammalian Cells by Antisense Oligonucleotides That Modify the Aberrant Splicing Patierns of Thalassemic Pre-mRNAs. Nucleosides & Nucleotides, 1997, 16, 1173-1182.	0.5	11
153	Cooperative Antitumor Effect of Mixed Backbone Oligonucleotides Targeting Protein Kinase A in Combination with Cytotoxic Drugs or Biologic Agents. Oligonucleotides, 1998, 8, 141-145.	4.4	11
154	Immune Modulatory Oligonucleotides in Prevention of Nasal Allergenâ€"Induced Eustachian Tube Dysfunction in Rats. Otolaryngology - Head and Neck Surgery, 2007, 137, 250-255.	1.1	11
155	Single-Stranded DNA and RNA Targeted Triplex-Formation: UV, CD and Molecular Modeling Studies of Foldback Triplexes Containing Different RNA, 2â€²-OMe-RNA and DNA Strand Combinations. Journal of Biomolecular Structure and Dynamics, 1997, 14, 715-726.	2.0	10
156	Mixed-Backbone Oligonucleotides Containing Phosphorothioate and Methylphosphonate Linkages as Second Generation Antisense Oligonucleotide. Nucleosides & Nucleotides, 1997, 16, 927-936.	0.5	9
157	Synergistic inhibition of HIV-1 by an antisense oligonucleotide and nucleoside analog reverse transcriptase inhibitors. Antiviral Research, 1998, 38, 63-73.	1.9	9
158	Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis. Biochemical and Biophysical Research Communications, 2004, 318, 60-66.	1.0	8
159	The role of immunomodulatory oligonucleotides in prevention of OVA-induced Eustachian tube dysfunction. International Journal of Pediatric Otorhinolaryngology, 2006, 70, 2019-2026.	0.4	8
160	Immune Modulatory Oligonucleotides in the Prevention and Treatment of OVAâ€Induced Eustachian Tube Dysfunction in Rats. Otolaryngology - Head and Neck Surgery, 2007, 137, 321-326.	1.1	8
161	Modulation of Endosomal Toll-Like Receptor-Mediated Immune Responses by Synthetic Oligonucleotides. Advances in Polymer Science, 2011, , 61-93.	0.4	8
162	Immune-Stimulatory Dinucleotide at the 5â€²-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses. ACS Medicinal Chemistry Letters, 2013, 4, 302-305.	1.3	8

#	Article	IF	Citations
163	Synthesis and Properties of 2'-O-Methylribonucleotide Methylphosphonate Containing Chimeric Oligonucleotides. Nucleosides, Nucleotides and Nucleic Acids, 1995, 14, 1031-1035.	0.4	7
164	Antisense oligonucleotides as antiviral agents. Advances in Antiviral Drug Design, 1996, , 1-39.	0.7	7
165	Intratumoral Pharmacokinetics of Oligonucleotides in a Tissue-Isolated Tumor Perfusion System. Oligonucleotides, 2000, 10, 105-110.	4.4	7
166	Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo. Organic and Biomolecular Chemistry, 2013, 11, 1049.	1.5	7
167	RNA Therapeutics Are Stepping Out of the Maze. Trends in Molecular Medicine, 2020, 26, 1061-1064.	3.5	7
168	The Cockayne syndrome group B DNA repair protein as an anti-cancer target. International Journal of Oncology, 2001, 19, 1089-97.	1.4	6
169	Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice. Vaccine, 2006, 24, 1470-1477.	1.7	6
170	Repression of Human Thymidylate Synthase mRNA Translation by Antisense 2â€²-O-Methyl Oligoribonucleotides. Oligonucleotides, 1998, 8, 371-378.	4.4	5
171	Sa1757 Targeting Innate Immune Receptors to Treat Inflammatory Bowel Disease: Preclinical Activity of IMO-9200, an Antagonist of TLRS 7, 8, and 9 in Mouse Models of Colitis. Gastroenterology, 2015, 148, S-324.	0.6	5
172	Suppression of Kv3.3 channels by antisense oligonucleotides reverses biochemical effects and motor impairment in spinocerebellar ataxia type 13 mice. FASEB Journal, 2021, 35, e22053.	0.2	5
173	Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Methods in Molecular Biology, 2022, 2434, 3-31.	0.4	5
174	Patent strategies in the antisense oligonucleotide based therapeutic approach. Expert Opinion on Therapeutic Patents, 1997, 7, 1175-1182.	2.4	4
175	Pseudo-cyclic oligonucleotides: in vitro and in vivo properties. Bioorganic and Medicinal Chemistry, 1999, 7, 2727-2735.	1.4	4
176	Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides. International Journal of Oncology, 2001, 18, 1061-9.	1.4	4
177	Hybridization-based fluorescence assay allows quantitation of single-stranded oligodeoxynucleotides in low nanomolar range. Analytical Biochemistry, 2004, 328, 93-95.	1.1	3
178	Synthesis, Biophysical Properties, and Stability Studies of Mixed Backbone Oligonucleotides Containing Novel Non-Ionic Linkages. Nucleosides & Nucleotides, 1997, 16, 1491-1495.	0.5	2
179	Mixed-Backbone Oligonucleotides Containing Segments of Deoxynucleosides Phosphorothioate and 2'-O-Methylribonucleosides Methylphosphonate: Synthesis and Properties. Phosphorus, Sulfur and Silicon and the Related Elements, 1999, 144, 363-366.	0.8	1
180	Impact of Site-Specific Nucleobase Deletions on the Arthritogenicity of DNA. Inflammation, 2004, 28, 159-168.	1.7	1

#	Article	IF	Citations
181	Chemistry of CpG DNA. Current Protocols in Nucleic Acid Chemistry, 2003, 12, Unit 4.16.	0.5	0